Press Release
“Infertility is surmountable, you will have a child!” – a serial businessman-pedophile guarantees
Surrogacy is a multifaceted phenomenon. For desperate childless couples – the last hope to become parents, for some enterprising businessmen convicted of pedophilia and fraud – another way to make money quickly. Nothing personal, just business. Let’s follow the history of the intermediary agency Gestlife, well-known in Ukraine and abroad.
What do people suffering from infertility expect, resorting to surrogacy as a last hope to become parents of a baby? Probably, confidence in the appearance of a healthy child, a careful attitude to their experiences, fears, pain from previous failures. But what if the founder of this agency doesn’t care about your worries and concerns? In addition to the surrogacy agency, he has a series of very different businesses:
- Eliminalia is an online reputation management agency specialising in removing unwanted information about the dark dealings of powerful people, many of whom have been convicted of serious crimes (its employees even pose as European Union officials to achieve their goals);
- Jurisdalia (which changed its name to Legisdalia), a law firm with a wide range of services that promises to protect your rights on the outside and in prison;
- Subastalia – a company registered for commercial purposes, with an undefined line of business;
- Wave Music – a production company dedicated to finding talented musicians;
- Mireia Vidal Brides – a bridal salon;
- Padres Para Siempre – an organisation involved in adopting orphans from Russia before it was banned by Russian law;
- Financonsulting, a financial holding company whose financial fraud enriched the businessman and his partner by more than 8 million euros;
- Subrogalia – and finally, the surrogacy agency (now known under the brand names Gestlife and Eurosurrogacy)
As you can see, the level of involvement in the problem of infertility and its overcoming is maximum. In between deleting unwanted information on the Internet, mortgage machinations and selling wedding accessories.
Why so many rebrandings? – potential clients dreaming of a child may ask. The answer is simple: all these companies have a long trail of accusations and lawsuits, ranging from the negligent performance of duties by the surrogacy agency Subrogalia to accusations of sexual harassment of a 17-year-old employee of Wave Music.
But this is not the most important thing that potential parents in need of surrogacy should know. The fact is that the owner of the surrogacy agency Gestlife is Jose Maria Gil Prados (who changed his name to Diego), convicted of abusing a 12-year-old boy and his sister. Later, the victim of the pervert, Didac Jimenez Sanchez, will become a co-owner and, in fact, a front man for a new version of the surrogacy agency Subrogalia in Spain – Gestlife, in Ukraine – Eurosurrogacy, as well as some other companies.
The surrogacy agency Gestlife talks about its clinic Intereco, without, of course, informing potential clients that before it there was the clinic Interfiv, which is under investigation for the same human trafficking, document falsification and illegal adoption.
Currently, the clinic Interfiv, originally created by Gil Prados and Sanchez, is not working: the sign has disappeared from the facade of the building, and in a Google search you can find information that the company is closed forever. Didac Sanchez and Jose Maria Gil Prados are distancing themselves from the agency Gestlife and the new clinic Intereco in every possible way, so that the trail of accusations of fraud and other unsightly stories that follows them does not scare off potential clients. The new owner of the surrogacy agency Gestlife clinic on December 31, 2017 is … the adopted son of Gil Prados, Alan Alexis Hill Prados. Financial flows remained in the family.
Meanwhile, a representative of the Russian branch of the Subrogalia surrogacy agency was sentenced to 4.5 years for human trafficking. Despite the fake clinic owners, the creator’s signature approach to business does not change. Old habits die hard, the series of crimes continues.
Gestlife also continues to deceive intended parents about the terms of its supposedly guaranteed programs. In 2020, an Italian woman, Irene, contacted the agency to become a mother through surrogacy services. After the war in Ukraine began, the agency offered the woman to pay for the surrogate mother to move to Georgia for a safer program, assuring that this step would not affect the legalization of the newborn or the cost of the contract. The assurances turned out to be another lie: the woman had to spend 14,000 euros over the cost of the program (80,000 euros) and hire her own team of lawyers (Gestlife’s lawyers must have been surprised by Georgia’s stricter laws on determining parental rights for children born under surrogacy programs). All this in order to be able to return to Italy with the child.
Apparently anticipating such cases, Gestlife included in the contract ‘a special clause on confidentiality, respect and non-attack on the image of the client, the company and its employees’, violation of which will result in a fine of 14,000 euros. By going public with her story Irene violated this clause. Making the client guilty of incompetence and making them pay for it – that’s the guarantee from Gestlife.
The parade of lies continues with Gestlife’s claims of representation in all countries where they offer reproductive programs. Albania is particularly interesting in this respect: the direction is actively promoted by the company (the fact that the country has no reliable legal framework for surrogacy is traditionally kept silent). If potential parents need to discuss the course of their program in Albania, the caring agency Gestlife offers to address its office… which is not an office, but the Embassy of Ukraine in Tirana. Apparently, Signors Prados and Sanchez feel it necessary to share your family affairs and reproductive anamnesis with a diplomatic institution.
And yes, neither José María Gil Prados nor Didac Jiménez Sánchez are reproductive doctors.
Which means they have no idea what your reproductive prospects are, nor are they capable of selecting treatment tactics based on your reproductive history. All they do is earn their percentage by finding surrogate mothers and sending them to reproductive clinics that still co-operate with them. In other words, they make promises, and the obligation to fulfil them is assigned to third parties on the principle of ‘if it works out – great, if it doesn’t work out – next ones’. By the way, one of the key partners of Eurosurrogacy (the Ukrainian version of Subrogalia) – the reproductive clinic BioTex stopped co-operation after learning about the criminal past of the counterparty. Surprisingly, a check of the counterparty was not conducted before the start of active co-operation.
Thus, to fulfil your dream of having a child (if you are lucky, with someone else’s hands) is promised by a middleman convicted of sexual offences, without the slightest expertise in reproductive medicine, with clinics that continue the tradition of human trafficking established by Subrogalia, lying about the conditions of legalisation of children in Albania and his legal address in this country, deceiving and leaving many people without money and children.
Be careful. Check every word of the person to whom you want to entrust the birth of your child. The lust for profit, a sea of lies and heinous crimes are not what should accompany the birth of children to people who have already suffered from the unjust caprice of their nature.
In addition to these cases, it is known that the BiotexCom clinic is accused of human trafficking. Because of this, the clinic’s management was changed, but the investigation continues. Another major clinic Feskov Human Reproduction Group was able to prove its innocence in participating in commercial surrogacy in the Czech Republic
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Trailers4Sale, a South Africa-based company, is gaining international attention for its versatile trailer solutions. Originally established to provide durable trailers for Mzansi Power’s generator needs, the company has expanded its product range to serve various industries, including agriculture, recreation, and construction. With a focus on adaptability and quality, Trailers4Sale offers an extensive selection of trailers and essential parts, making it a valuable partner in the evolving global logistics landscape. While primarily serving Southern Africa, the company’s products are increasingly relevant to internationals market, presenting an opportunity for businesses seeking reliable transport solutions.
Vanderbijlpark, Gauteng, South Africa, 18th Oct 2024 – Trailers4Sale, a company rooted in the dynamic and diverse economy of South Africa, is redefining the trailer industry by leveraging its expertise in designing adaptable and versatile transport solutions. With a focus on innovation, the company has developed trailers suited to industries ranging from agriculture to recreation, while also offering a wide range of essential trailer parts. Now, with logistical demands increasing worldwide, Trailers4Sale’s products are poised to play a role in shaping global transport strategies—catching the attention of the local market.
Rethinking Transport with Versatile Trailers
Trailers4Sale’s journey began with a focus on building strong, durable trailers for South Africa’s generator market through its parent company, Mzansi Power. As demand for trailers grew beyond energy transport, the company expanded to produce a wide array of trailer types that meet various industry needs. Today, Trailers4Sale offers everything from multi-purpose trailers and flatbed trailers to highly specialized models like cattle trailers and Bomac trailers for heavy-duty applications.
Southern Africa’s landscape has long been a hub for trade, agriculture, and industrial growth, which has allowed Trailers4Sale to develop trailers designed for flexibility and reliability. These qualities align with the evolving needs of industries worldwide, where businesses increasingly rely on adaptable transport solutions to improve efficiency.
An Industry Adapting to Change
The trailer industry globally has seen a surge in demand as businesses in sectors like construction, agriculture, and logistics recognize the importance of optimizing transport. What makes Trailers4Sale stand out is its ability to address these challenges with customizable solutions. Trailers4Sale’s approach centers on providing trailers that can be adapted to various needs—whether it’s for transporting heavy equipment, recreational vehicles, or livestock.
Trailers4Sale is uniquely positioned to meet its demands by offering trailers that suit a variety of terrains and functions, products which are increasingly relevant to the American landscape. From motorbike trailers for recreational use to multi-purpose trailers for commercial applications, the company’s range is designed to align with the growing expectations for versatile, durable transport solutions.
Bridging the Gap with Practical Solutions
One of Trailers4Sale’s most significant contributions is in offering not just trailers, but a full suite of parts and accessories. Businesses looking for reliable access to parts like rims, lights, wiring, or jockey wheels will find that Trailers4Sale’s inventory is designed to provide easy maintenance and repair solutions, ensuring transport operations run smoothly.
This holistic approach has allowed the company to form strong partnerships with both local and international businesses, providing high-quality products that have earned the trust of its customers.
Built on Expertise and Service
A key driver behind Trailers4Sale’s success has been its ability to combine innovation with customer care. The company prides itself on offering personalized guidance to help businesses select trailers that meet their specific needs. With the increasing complexity of global logistics, having a partner who can offer expert advice, backed by years of experience in a region known for its economic growth, positions Trailers4Sale as a unique player in the industry.
“We believe that trailers are more than just transport tools; they are critical components in a business’s overall efficiency,” says Evert Janse van Rensburg, Founder of Trailers4Sale. “South Africa’s thriving industries have shaped our understanding of what businesses need to succeed, and we are eager to share this expertise globally.”
Looking to the Future: A Global Perspective
As global industries seek smarter transport solutions, Trailers4Sale is well-placed to support this shift by offering products that meet high standards of performance and reliability. For companies navigating new logistical challenges, Trailers4Sale’s comprehensive approach—offering both trailers and essential parts—presents a valuable opportunity to enhance their operations.
For more information about Trailers4Sale’s products and services, visit their website.
Media Contact
Organization: Trailers4Sale
Contact Person: Evert Janse van Rensburg
Website: https://trailers4sale.co.za
Email: Send Email
Contact Number: +27658316889
Address: 19A Michelin St
Address 2: Vanderbijlpark N. W. 7
City: Vanderbijlpark
State: Gauteng
Country: South Africa
Release Id: 18102418608
The post South Africa’s Trailers4Sale Offers Global Insight into Transport Efficiency appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation.
New Zealand, 18th Oct 2024 – In the context of a rapidly aging global population and a growing awareness of health among consumers, the demand for premium oral anti-aging nutritional products is surging. OXYENERGY, a specialized nutritional brand from New Zealand, has developed and produced AGELESS SWITCH, a cutting-edge product based on the concept of “comprehensive anti-aging and stem cell activation,” aiming to create a truly functional anti-aging solution. This innovative approach has quickly garnered widespread attention worldwide, with numerous prominent media outlets covering the product, and endorsements from respected professionals, including professors, nutritionists, and international pageant winners. As a result, AGELESS SWITCH PQQ has gained significant traction, emerging as a dominant new trend in the oral beauty and anti-aging market.
PQQ (Pyrroloquinoline Quinone) holds a highly esteemed position in the fields of biomedical and nutritional sciences, earning the title of “King of Immunity.” Due to its complex extraction process, the purified form of PQQ commands an exceptionally high price on the international market—exceeding the value of gold by over a thousand times. For a long time, this made PQQ available only for research purposes. However, further studies revealed that PQQ can effectively target and neutralize free radicals in the body, mitigating oxidative stress damage to cellular structures. This potent protection of cellular health surpasses that of traditional antioxidants, leading to the widespread adoption of PQQ in anti-aging products.
The AGELESS SWITCH PQQ product builds on traditional PQQ formulations, seeking innovative breakthroughs in both technology and formulation. It focuses on stem cell activation technology and sets a new market benchmark with a high concentration of 50mg per capsule and over 99% purity achieved through patented extraction processes. This product is further enhanced by premium ingredients such as Ergothioneine, Pterostilbene, and Apple Stem Cell Extract. Utilizing advanced 6-in-1 Black Gold Anti-Aging Technology, it upgrades its antioxidant capacity by 60,000 times, establishing the Black Gold Anti-Aging Pyramid and offering a three-step targeted anti-aging solution for full-body rejuvenation.
OXYENERGY’s AGELESS SWITCH PQQ stands out in the industry with its pioneering biotechnology and advanced formulation, positioning itself as a trailblazer driving further development in the anti-aging sector. Its excellent product reputation has sparked a global following, earning it the nickname “the black bandage of oral supplements.” This has ignited an unprecedented AGELESS SWITCH PQQ trend in the global anti-aging market, with countless consumers adopting it in their daily routines to affirm their status as anti-aging enthusiasts. Industry experts have remarked, “The global era of OXYENERGY AGELESS SWITCH has arrived!”
As a global pioneer in the field of dietary nutrition, the New Zealand brand OXYENERGY consistently stays at the forefront of industry development with its forward-thinking vision and scientific expertise. Committed to advancing the anti-aging sector and other health-related fields, OXYENERGY continues to drive breakthroughs and innovations in the global health industry. The brand is leading more consumers toward a younger, healthier future.
Media Contact
Organization: OXYENERGY
Contact Person: sunny chen
Website: https://www.oxyenergy-labs.com/
Email: Send Email
Country: New Zealand
Release Id: 18102418595
The post OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation. appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the “Hong Kong and Macau Medicine and Equipment Connect” policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.
In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.
If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.
Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.
CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the “Hong Kong and Macau Medicine and Equipment Connect” policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.
About ruxolitinib cream
Ruxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].
On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.
Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.
About vitiligo
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5、6].
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.
Reference：
- Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-t…
- Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
- Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura
- Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-7
- Consensus on the diagnosis and treatment of vitiligo (2021 version)
- Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
South Africa’s Trailers4Sale Offers Global Insight into Transport Efficiency
OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation.
China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area
Africa Is The New Site Of Media Confrontation: Daily Post Nigeria Assesses the Situation
Real Street Capital Appoints Gregory Stula as Chairman of the Board
Seaco-online.com Sets Sail with E-Commerce Revamp Poised to Elevate Singapore’s Seafood Shopping Experience
-
Press Release1 week ago
Freedom FX Broker: Celebrating Three Consecutive Years as the Best Forex Broker
-
Press Release1 week ago
Empowering Companies to Cross Capital Market Boundaries: Carat W Holding’s Expertise in Listing and Fundraising in Taiwan, the U.S. and the U.K.
-
Press Release1 week ago
NEXT15 Innovative Advertising Work Platform, Creating a Win-Win Model for Users and Brands
-
Press Release1 week ago
Solana and Ethereum-Based Device Authentication and Authorization Consensus Algorithm Developed by Dono Vault
-
Press Release2 days ago
Indie Fest Carolina to Feature Dancehall/Reggae Sensation Remedy Live in Charlotte
-
Press Release2 days ago
How DLDCUSDT propels the EV industry forward
-
Press Release1 day ago
Growork: The groundbreaking SaaS platform set to revolutionise business connections in the UAE
-
Press Release2 days ago
SafetyXpress Launches Innovative U-Shaped Bollards for Maximum Protection in Commercial and Industrial Spaces